bullish
Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?
278 Views21 Mar 2024 09:30
SUMMARY
- Lotus Pharmaceutical (1795 TT) achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.
- For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat.
- 1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Lotus Pharmaceutical (1795 TT): Continued Stellar Growth in Q2; Pipeline Expansion to Drive Growth24 Sep 2023
- Lotus Pharmaceutical (1795 TT): 2022 Ends with Mid-Teen Revenue Growth; Further Steam Still Left05 Feb 2023
- Lotus Pharmaceutical (1795 TT): 3Q22 Review- Best-Ever Quarter, Aided by Oncology Drug Launch in US18 Nov 2022
x